Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 2/20 | 0.53 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.53 |
| ▸ | LMNA | P02545 | 4/20 | 0.51 |
| ▸ | MEN1 | O00255 | 4/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.51 |
| ▸ | NPC1 | O15118 | 2/20 | 0.51 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.51 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.51 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.51 |
| ▸ | PDE4A | P27815 | 1/20 | 0.51 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.51 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.51 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | APEX1 | P27695 | 1/20 | 0.50 |
| ▸ | CA2 | P00918 | 1/20 | 0.49 |
| ▸ | CA4 | P22748 | 1/20 | 0.49 |
| ▸ | CA5A | P35218 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Iodide SCHEMBL2453858 | 0.98 | EPHX1 (0.52) | EPHX1EPHX2LMNAMEN1KMT2A | |
| SCHEMBL61965 | 0.86 | SMN1; SMN2 (0.54) | EPHX2LMNAMEN1KMT2ANPC1 | |
| Iodide SCHEMBL60933 | 0.84 | SMN1; SMN2 (0.53) | EPHX2LMNAMEN1KMT2ANPC1 | |
| SCHEMBL7780812 | 0.81 | HDAC3 (0.56) | EPHX1EPHX2LMNAMEN1KMT2A | |
| SCHEMBL27699202 | 0.80 | IDO1 (0.55) | LMNAGAAALDH1A1IDO1 | |
| SCHEMBL12057510 | 0.80 | KDR (0.60) | LMNAMEN1KMT2AHTTCA2 | |
| SCHEMBL7670022 | 0.80 | ALDH1A1 (0.48) | EPHX1LMNAMEN1KMT2ANPC1 | |
| Iodide SCHEMBL3533967 | 0.79 | KDR (0.59) | LMNAMEN1KMT2AHTTCA2 | |
| SCHEMBL12333872 | 0.79 | EPHX1 (0.50) | EPHX1EPHX2LMNAMEN1KMT2A | |
| Iodide SCHEMBL6340120 | 0.79 | ALDH1A1 (0.47) | EPHX1LMNAMEN1KMT2ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1686990-B1 | 2-GUANIDINYLIMIDAZOLIDINEDIONE COMPOUNDS AND METHODS OF MAKING AND USING THEREOF | US ARMY MED RES MAT COMMAND (US) | 2012-09-19 | — | — | EP | claimed |
| EP-1686990-A4 | 2-GUANIDINYLIMIDAZOLIDINEDIONE COMPOUNDS AND METHODS OF MAKING AND USING THEREOF | US ARMY MED RES MAT COMMAND (US) | 2009-06-03 | — | — | EP | claimed |
| US-7101902-B2 | 2-guanidinylimidazolidinedione compounds and methods of making and using thereof | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE ARMY (US) | 2006-09-05 | — | — | US | claimed |
| EP-1686990-A2 | 2-GUANIDINYLIMIDAZOLIDINEDIONE COMPOUNDS AND METHODS OF MAKING AND USING THEREOF | U.S. Army Medical Research and Materiel Command (US) | 2006-08-09 | — | — | EP | claimed |
| WO-2005072082-A2 | 2-GUANIDINYLIMIDAZOLIDINEDIONE COMPOUNDS AND METHODS OF MAKING AND USING THEREOF | U.S. ARMY MEDICAL RESEARCH AND MATERIEL COMMAND (US) | 2005-08-11 | — | — | WO | claimed |
| US-20050148645-A1 | 2-Guanidinylimidazolidinedione compounds and methods of making and using thereof | ARMY, UNITED STATES | 2005-07-07 | — | — | US | claimed |
| US-8283370-B2 | Imidazolidinedione derivatives as antimalarial agents, preparation thereof, and methods of use | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE ARMY (US) | 2012-10-09 | — | — | US | disclosed |
| EP-1686990-B1 | 2-GUANIDINYLIMIDAZOLIDINEDIONE COMPOUNDS AND METHODS OF MAKING AND USING THEREOF | US ARMY MED RES MAT COMMAND (US) | 2012-09-19 | — | — | EP | disclosed |
| US-20110230533-A1 | IMIDAZOLIDINEDIONE DERIVATIVES AS ANTIMALARIAL AGENTS, PREPARATION THEREOF, AND METHODS OF USE | LIN AI JENG | 2011-09-22 | — | — | US | disclosed |
| WO-2010051129-A2 | NEW IMIDAZOLIDINEDIONE DERIVATIVES AS ANTIMALARIAL AGENTS, PREPARATION THEREOF, AND METHODS OF USE | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY OF THE ARMY, ON BEHALF OF U.S. ARMY MEDICAL RESEARCH AND MATERIEL COMMAND (US) | 2010-05-06 | — | — | WO | disclosed |
| EP-1686990-A4 | 2-GUANIDINYLIMIDAZOLIDINEDIONE COMPOUNDS AND METHODS OF MAKING AND USING THEREOF | US ARMY MED RES MAT COMMAND (US) | 2009-06-03 | — | — | EP | disclosed |
| US-7101902-B2 | 2-guanidinylimidazolidinedione compounds and methods of making and using thereof | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE ARMY (US) | 2006-09-05 | — | — | US | disclosed |
| EP-1686990-A2 | 2-GUANIDINYLIMIDAZOLIDINEDIONE COMPOUNDS AND METHODS OF MAKING AND USING THEREOF | U.S. Army Medical Research and Materiel Command (US) | 2006-08-09 | — | — | EP | disclosed |
| WO-2005072082-A2 | 2-GUANIDINYLIMIDAZOLIDINEDIONE COMPOUNDS AND METHODS OF MAKING AND USING THEREOF | U.S. ARMY MEDICAL RESEARCH AND MATERIEL COMMAND (US) | 2005-08-11 | — | — | WO | disclosed |
| US-20050148645-A1 | 2-Guanidinylimidazolidinedione compounds and methods of making and using thereof | ARMY, UNITED STATES | 2005-07-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050148645-A1 | 2-Guanidinylimidazolidinedione compounds and methods of making and using thereof | GUCY1B2, GUCY1A2, AGK | EPHX1 2002/4885EPHX2 1468/4885LMNA 733/4885 |
| US-20110230533-A1 | IMIDAZOLIDINEDIONE DERIVATIVES AS ANTIMALARIAL AGENTS, PREPARATION THEREOF, AND METHODS OF USE | ITPA, EIF2AK2, ABL1 | EPHX1 2344/4885EPHX2 2813/4885LMNA 892/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.